Equipoise

ACTIVE INGREDIENT

Each mL contains:

• Boldenone Undecylenate 250 mg

DESCRIPTION

Equipoise 250 mg is an injectable anabolic steroid containing boldenone undecylenate, a long-acting derivative of testosterone. It is formulated as a colorless to pale yellow oil, providing a sustained release of boldenone into the bloodstream after intramuscular injection. Known for its anabolic properties, Equipoise promotes muscle growth, enhances appetite, and increases red blood cell production. It is commonly used in veterinary medicine but has gained popularity in bodybuilding and athletic circles for its ability to enhance performance and physique without significant androgenic side effects.

PHARMACOLOGICAL PROPERTIES

Mechanism of Action: Boldenone undecylenate exerts its effects by binding to androgen receptors in muscle tissues, promoting protein synthesis, nitrogen retention, and erythropoiesis (red blood cell production). Its mild androgenic properties make it suitable for use in both men and women, helping to build lean muscle mass while minimizing water retention.

Pharmacokinetics:

• Absorption: Boldenone undecylenate is well-absorbed after intramuscular injection.
• Distribution: It is widely distributed in body tissues, with a high affinity for fat and muscle.
• Metabolism: Primarily metabolized in the liver, with a half-life of approximately 14 days.
• Excretion: Excreted mainly through urine as metabolites.

INDICATIONS

Equipoise 250 mg is indicated for:

Anemia: To stimulate erythropoiesis in patients with anemia.

Muscle-wasting conditions: To preserve lean muscle mass in patients with chronic wasting diseases.

Performance enhancement: Used in bodybuilding and athletics to increase strength, muscle mass, and endurance.

DOSAGE AND ADMINISTRATION

Dosage:

• Medical Use: Dosage varies depending on the specific condition being treated. Common doses range from 200 mg to 600 mg per week, as prescribed by a healthcare provider.
• Anabolic/Bodybuilding Use: Typical doses range from 300 mg to 600 mg per week, administered in divided doses.

Administration:

• Administer via deep intramuscular injection. Shake the vial well before administration to ensure a uniform suspension. Rotate injection sites to avoid irritation.

CONTRAINDICATIONS

• Hypersensitivity to boldenone or any component of the formulation.

• Pregnancy and lactation (Pregnancy Category X).

• Active breast cancer in females or suspected prostate cancer in males.

• Severe cardiovascular, renal, or hepatic disease.

• Hypercalcemia (high blood calcium levels).

WARNINGS AND PRECAUTIONS

1. Hepatic Toxicity: Boldenone can cause liver toxicity, including elevations in liver enzymes. Regular monitoring of liver function tests is recommended during treatment.

2. Cardiovascular Risks: Use of anabolic steroids can increase the risk of cardiovascular diseases, including hypertension, dyslipidemia, and thrombosis. Monitor cardiovascular health, particularly in long-term users.

3. Androgenic Effects: Although equipoise has a lower androgenic effect compared to other steroids, prolonged use can lead to side effects such as acne, hair loss, and virilization in women.

4. Lipid Profile: Boldenone can negatively impact cholesterol levels, lowering HDL and increasing LDL cholesterol. Regular monitoring of lipid profiles is recommended.

5. Psychological Effects: Some users may experience mood swings, aggression, or changes in mood. Monitor psychological health during treatment.

ADVERSE REACTIONS

Common adverse reactions:

• Acne
• Oily skin
• Hair loss (androgenic alopecia)
• Increased appetite

Serious adverse reactions:

• Hepatotoxicity: Liver damage, jaundice.
• Cardiovascular: Increased risk of heart attack, stroke, or blood clot formation.
• Endocrine: Gynecomastia (in men), suppression of natural testosterone production, testicular atrophy.
• Psychiatric: Aggression, irritability, mood swings, or depression.

INTERACTIONS

1. Anticoagulants: Boldenone may enhance the effects of anticoagulants (e.g., warfarin), increasing the risk of bleeding. Close monitoring of blood coagulation is necessary.

2. Insulin and Oral Antidiabetics: Boldenone can impact glucose tolerance and may require adjustments to insulin or antidiabetic medication dosages.

3. Corticosteroids: Combined use of corticosteroids with equipoise may increase the risk of fluid retention and exacerbate electrolyte imbalances.

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation: Equipoise is contraindicated in pregnant and breastfeeding women due to potential teratogenic effects (Pregnancy Category X).

Pediatric Use: Use in children or adolescents may interfere with normal growth and development due to the risk of premature closure of growth plates (epiphyseal closure).

Geriatric Use: Older individuals may be more susceptible to adverse effects, particularly on the liver and cardiovascular system. Use with caution in elderly patients.

OVERDOSAGE

There is no specific antidote for boldenone overdose. In case of an overdose, supportive and symptomatic treatment should be provided. Monitor liver function and cardiovascular health closely.

STORAGE

Store below 25°C (77°F). Protect from light. Do not refrigerate or freeze. Keep out of reach of children.

PACKAGING

Equipoise 250 mg is supplied in 10 mL vials, each containing 250 mg of boldenone undecylenate in a colorless to pale yellow oil.

MANUFACTURER

Oxydine Metabolics Switzerland

Oxydine.org
Hi@Oxydine.org